These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6639837)

  • 21. [A single dose of theophylline in the evening in chronic obstructive airway disease. Serum concentration and lung function parameter].
    Kaik G
    Fortschr Med; 1984 Nov; 102(43):1120-2. PubMed ID: 6510864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin.
    Bachmann K; Jauregui L; Sides G; Sullivan TJ
    J Clin Pharmacol; 1993 Sep; 33(9):861-5. PubMed ID: 8227485
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient compliance with oral theophylline therapy.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1984 Jan; 17(1):15-20. PubMed ID: 6691884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma theophylline concentrations in patients with chronic obstructive airways disease after administration of a new sustained release theophylline formulation.
    Taylor DR; Kinney CD; McDevitt DG
    Br J Clin Pharmacol; 1982 Apr; 13(4):569-71. PubMed ID: 7066172
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison of two sustained-release theophylline preparations in adult patients with obstructive airways disease.
    Harkaway PS; Conlon PF; Hirsh JD; Allen WT
    J Clin Pharmacol; 1985 Sep; 25(6):444-7. PubMed ID: 4056079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum level monitoring of a new slow release theophylline formulation in patients with chronic lung disease.
    Marlin GE; Butcher MA; Klumpp JA; Thompson PJ
    Br J Clin Pharmacol; 1980 Sep; 10(3):265-71. PubMed ID: 7437244
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliability of theophylline clearance in determining chronic oral dosage regimens.
    Slotfeldt ML; Johnson CE; Grambau G; Weg JG
    Am J Hosp Pharm; 1979 Jan; 36(1):66-8. PubMed ID: 758787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.
    McKay SE; Howie CA; Thomson AH; Whiting B; Addis GJ
    Thorax; 1993 Mar; 48(3):227-32. PubMed ID: 8497820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired theophylline clearance in patients with cor pulmonale.
    Vicuna N; McNay JL; Ludden TM; Schwertner H
    Br J Clin Pharmacol; 1979 Jan; 7(1):33-7. PubMed ID: 760740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Theophylline concentration following equal doses of intravenous aminophylline and oral theophylline in preterm infants.
    al-Omran A; al-Alaiyan S
    Am J Perinatol; 1997 Mar; 14(3):147-9. PubMed ID: 9259917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum theophylline concentrations and pulmonary function tests after administration of two sustained-release formulations containing theophylline in patients affected by chronic obstructive lung disease.
    Fontana G; Cresci F; Lo Sapio P; Panuccio P
    Int J Clin Pharmacol Res; 1987; 7(5):351-6. PubMed ID: 3667008
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma theophylline levels after sustained-release aminophylline.
    Trembath PW; Boobis SW
    Clin Pharmacol Ther; 1979 Nov; 26(5):654-9. PubMed ID: 498707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aging, cigarette smoking and oral theophylline requirement.
    Talseth T; Boye NP; Kongerud J; Bredesen JE
    Eur J Clin Pharmacol; 1981; 21(1):33-7. PubMed ID: 7333344
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disposition and clinical pharmacokinetics of microcrystalline theophylline.
    Jonkman JH; Berg WC; Schoenmaker R; de Zeeuw RA; Greving JE; Orie NG
    Eur J Clin Pharmacol; 1980 May; 17(5):379-84. PubMed ID: 7418716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of theophylline in 'irreversible' chronic obstructive pulmonary disease. An update.
    Hill NS
    Arch Intern Med; 1988 Dec; 148(12):2579-84. PubMed ID: 3058071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of theophylline in chronic obstructive lung disease.
    Umut S; Gemicioğlu B; Yildirim N; Barlas A; Ozüner Z
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):149-52. PubMed ID: 1592541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum theophylline levels with oral sustained release theophylline after transfer from intravenous aminophylline in patients with chronic lung disease.
    Silins RA; Butcher MA; Marlin GE
    Br J Clin Pharmacol; 1984 Oct; 18(4):645-7. PubMed ID: 6487509
    [No Abstract]   [Full Text] [Related]  

  • 38. A cross-over study of oral and intravenous administration of theophylline in male volunteers. Absolute bioavailability of theophylline tablets.
    Kaumeier HS; Kehrhahn OH; Neugebauer G; Schuppan D; Schwarz JA; Staib AH
    Arzneimittelforschung; 1984; 34(1):92-5. PubMed ID: 6538428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tolerance of a new oral long-acting theophylline in patients with obstructive airway diseases].
    Nolte D; Dusik B
    Fortschr Med; 1983 Jul; 101(25):1203-6. PubMed ID: 6884955
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The rise and fall of serum theophylline concentration: a comparison of sustained-release formulations in volunteers with rapid theophylline clearance.
    Mucklow JC; Kuhn S
    Br J Clin Pharmacol; 1985 Dec; 20(6):589-96. PubMed ID: 4091990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.